4//SEC Filing
Lemkey John G 4
Accession 0001209191-20-056583
CIK 0001717452other
Filed
Nov 2, 7:00 PM ET
Accepted
Nov 3, 4:05 PM ET
Size
9.1 KB
Accession
0001209191-20-056583
Insider Transaction Report
Form 4
Lemkey John G
Chief Financial Officer
Transactions
- Award
Common Stock
2020-10-30$12.25/sh+96$1,176→ 3,349 total - Award
Employee Stock Option (Right to Buy)
2020-10-30+96→ 96 totalExercise: $14.41Exp: 2030-10-30→ Common Stock (96 underlying)
Holdings
- 15,238,782(indirect: By LP)
Common Stock
Footnotes (3)
- [F1]These shares were acquired on 10/30/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- [F2]The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Tang Capital Management, LLC ("TCM") is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. John Lemkey is the Chief Operating Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Mr. Lemkey has a pecuniary interest in a portion of the shares beneficially held by TCP.
- [F3]The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date.
Documents
Issuer
Odonate Therapeutics, Inc.
CIK 0001717452
Entity typeother
Related Parties
1- filerCIK 0001495904
Filing Metadata
- Form type
- 4
- Filed
- Nov 2, 7:00 PM ET
- Accepted
- Nov 3, 4:05 PM ET
- Size
- 9.1 KB